Academic Journals Database
Disseminating quality controlled scientific knowledge

Pemetrexed Alone versus Pemetrexed Combined with Oxaliplatin as Salvage Therapy 
in Stage IV Lung Adenocarcinoma

ADD TO MY LIST
 
Author(s): Youru LIU | Yinling JIANG | Zhiqiang GAO | Xiangying WANG | Baohui HAN | Liyan JIANG

Journal: Chinese Journal of Lung Cancer
ISSN 1009-3419

Volume: 14;
Issue: 9;
Start page: 704;
Date: 2011;
Original page

Keywords: Lung neoplasms | Pemetrexed | Oxaliplatin | Gefitinib | Erlotinib

ABSTRACT
Background and objective At present, there is no standard salvage treatment strategies for lung cancer. The aim of this study is to compare the efficacies and safeties of pemetrexed alone with pemetrexed combined with oxaliplatin as salvage therapy in stage IV lung adenocarcinoma to provide evidences for combination therapy. Methods From January 2009 to February 2011, 83 patients with stage IV lung adenocarcinoma received pemetrexed alone (single agent arm, n=47) or pemetrexed combined with oxaliplatin (combination arm, n=36) as salvage therapy. All 83 patients had performance status (PS) scores of 0-2. Results Eighty-one patients were included in the final analysis. The median progression-free survival (PFS) in the single agent arm was 3.6 months versus 4.1 months in the combination arm (P=0.268). The objective response rate (ORR) was 6.5% versus 20% (P=0.092), and the disease control rate (DCR) was 56.5% versus 65.7% (P=0.493), respectively. The response rates of the hematological and gastrointestinal toxicities in the single agent and combination arms were 33.9% versus 47.2% (P=0.460) and 21.2% versus 25.0% (P=0.213), respectively. Conclusion For salvage therapy, pemetrexed combined with oxaliplatin is tolerable in stage IV lung adenocarcinoma patients with good PS scores. Compared with pemetrexed alone, pemetrexed combined with oxaliplatin therapy showed higher response rate, but did not significantly prolong the PFS.
Save time & money - Smart Internet Solutions      Why do you need a reservation system?